GlassScriptPhysician profile
John J Griffin
NPI 1689753923
$1,150.64
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356 · 2020: $298 · 2021: $262 · 2022: $142 · 2023: $92.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $92.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $92.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $201.84 | 2019-2023 | Mounjaro |
| Amgen INC. | $132.55 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $123.57 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $97.65 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.22 | 2019-2022 | |
| Pfizer INC. | $68.23 | 2019-2022 | |
| Novo Nordisk INC | $59.05 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $54.82 | 2021 | |
| Sanofi-Aventis U.S. LLC | $40.05 | 2019 | |
| Sumitomo Pharma America, INC. | $39.22 | 2023 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $34.27 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $33.75 | 2021 | |
| Almatica Pharma LLC | $32.85 | 2021 | |
| Janssen Pharmaceuticals, INC | $30.35 | 2019 | |
| Amarin Pharma, INC. | $30.03 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $29.31 | 2020 | |
| Eisai INC. | $26.68 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $13.96 | 2021 | |
| Esperion Therapeutics, INC. | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.